

關注個股

IMP



*Yuanta
Securities Vietnam*



CƠ CẤU CỔ ĐÔNG



IMP

短期阻力關卡:	50.50
短期支撐關卡:	45.92
短期趨勢 (5-10 天):	上漲
中期阻力關卡:	53.15
中期支撐關卡:	43.38
中期趨勢 (1-3 月):	上漲

THÔNG TIN CƠ BẢN

Nhóm ngành	Dược phẩm và Y tế	ROE (TTM)	11.99
Ngành	Dược phẩm	EPS (TTM)	2,972
GTGD	21,789,000,000	Tỷ lệ free float	50.00%
KLGD (CP)	448,010	P/E (TTM)	15.6x
Vốn hóa (Tỷ VND)	3,087	P/B	1.9x
SLCPLH (CP)	66,671,570	P/S	2.2x
Tỷ suất cổ tức	0%	EV/EBITDA (TTM)	10.92
KLTB 20 phiên	56,365	Giá trị DN (Tỷ VND)	3,211
Beta 6th (TTM)	0.79	ROA (TTM)	9.97

Mã CP
IMP

Tên công ty
IMEXPHARM

Sàn GD
HOSE

STOCK RATING

84

ĐIỂM CƠ BẢN

95

SỨC MẠNH GIÁ

73

Xu hướng ngắn hạn

上漲

Khuyến nghị

持有


Ngày

29/10/2020

Giá đóng cửa

49,000

KẾT QUẢ VÀ KẾ HOẠCH KINH DOANH





IMP – 從4家符合EU-GMP標準的工廠的增長動力



熱點信息

在2020年第三季度，IMP的業績受到新冠病疫的影響，淨營收同比下降10%，稅後利潤同比增長23%。2020年的前9個月中，IMP的淨營收為9,100億越南盾，同比增長2%；稅後利潤達1,390億越南盾，同比增長26%。



2020年第三季度，醫藥渠道的營收同比下降27%，而醫院渠道的營收同比增長24%。由於促銷和廣告成本降低，2020年第三季度和2020年第一季度的利潤率同比增長。

隨著新的CNC製藥工廠（Vinh Loc（IMP 2）和Binh Duong（IMP 4））預計於2020年第4季度開始商業運營，IMP將有4家符合EU-GMP標準的製藥工廠，這些具有生產優質藥物的工廠將幫助IMP競標進入第1組和第2組醫院渠道（ETC）。以當前價格計算，IMP的P/E TTM交易價為15.5倍（高於行業平均水平13.9倍）和EV/EBITDA 10.9倍（低於行業平均水平13.0倍）。



投資意見

IMP的股票評級為84分，因此我們仍然維持對該股票增長評估為積極，特別是基本的基礎預測在2020年第四季度繼續保持積極。但是，由於價格強度低於80點且流動性較低，這是我們不建議短期投資者買進該股票的兩個主要原因。

IMP的價格圖表大幅上漲，超過50天的平均線，與20天的平均價格相比，交易量激增。同時，價格走勢圖顯示出進入積極的劇烈波動階段的跡象，短期趨勢轉為上漲。



Yuanta
Securities Vietnam



IMP - 從4家符合EU-GMP標準的工廠的增長動力





Yuanta
Securities Vietnam



短期建議列表



短期建議列表



股碼	股價	短期趨勢	中期趨勢	建議買進日期	T+ 交易	短期買進價格	Stop loss	%報酬	短期建議	目前趨勢
HPG	30.60	上漲	上漲	5/8/2020	T+62	23.00	29.85	33.04%	持有	強勁波動
VIB	32.80	上漲	上漲	7/8/2020	T+60	19.50	31.16	68.21%	持有	Sideways
DCM	11.65	上漲	上漲	14/8/2020	T+55	8.70	11.43	33.91%	持有	強勁波動
VGC	22.85	上漲	上漲	28/9/2020	T+24	23.50	22.50	-2.77%	持有	Sideways
BMP	54.50	上漲	上漲	26/10/2020	T+4	57.40	53.70	-5.05%	持有	Sideways
GIL	30.30	上漲	上漲	27/10/2020	T+3	29.55	28.39	2.54%	持有	強勁波動





Yuanta
Securities Vietnam



個人客戶分析部

Nguyễn Th ê Minh
研究分析經理
+84 28 3622 6868 ext 3826
minh.nguyen@yuanta.com.vn

Quách Đứ c Khánh
高級分析專員
+84 28 3622 6868 ext 3833
khanh.quach@yuanta.com.vn

Phạm Tấn Phát
高級分析專員
+84 28 3622 6868 ext 3880
phat.pham@yuanta.com.vn

Lý Thị Hi ề n
研究分析主管
+84 28 3622 6868 ext 3908
hien.ly@yuanta.com.vn

Nguyễn Tr ị nh Ng ọ c H ồ ng
分析專員
+84 28 3622 6868 ext 3832
hong.nguyen@yuanta.com.vn

聯繫

Global Disclaimer



*Yuanta
Securities Vietnam*



© 2018 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold ourselves responsible for its completeness or accuracy. It is not an offer to sell or solicitation of an offer to buy any securities. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice.

This report provides general information only. Neither the information nor any opinion expressed herein constitutes an offer or invitation to make an offer to buy or sell securities or other investments. This material is prepared for general circulation to clients and is not intended to provide tailored investment advice and does not take into account the individual financial situation and objectives of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, investments or investment strategies discussed or recommended in this report. The information contained in this report has been compiled from sources believed to be reliable but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. This report is not (and should not be construed as) a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on such business in that jurisdiction.

Yuanta research is distributed in the United States only to Major U.S. Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended and SEC staff interpretations thereof). All transactions by a US person in the securities mentioned in this report must be effected through a registered broker-dealer under Section 15 of the Securities Exchange Act of 1934, as amended. Yuanta research is distributed in Taiwan by Yuanta Securities Investment Consulting. Yuanta research is distributed in Hong Kong by Yuanta Securities (Hong Kong) Co. Limited, which is licensed in Hong Kong by the Securities and Futures Commission for regulated activities, including Type 4 regulated activity (advising on securities). In Hong Kong, this research report may not be redistributed, retransmitted or disclosed, in whole or in part or and any form or manner, without the express written consent of Yuanta Securities (Hong Kong) Co. Limited.